ANG-2
Angiopoietin-2 predicts the efficacy of angiogenesis inhibitors in colorectal cancer therapy.
Ang-2 level as predictive biomarker for angiognese-targeted therapeutical approaches of CRC.
Low pretherapeutic serum Ang-2 levels are associated with: reduced risk of death, increased progression-free survival.
Cancer Therapy- Strong diagnostic potential of the predictive biomarker has been demonstrated in pretherapeutic blood samples from colorectal cancer patients vs. healthy controls
A novel predictive biomarker to help identify the patient population with the most favorable clinical outcome to angiogenesis-targeted treatment in mCRC patients.Experiments revealed that patients with low pretherapeutic Ang-2 serum levels receiving a bevacizumab-containing treatment were associated with a better response rate compared to patients with high pretherapeutic Ang-2 levels
Licensing
06/09/2010 00:00:00
EP20100757580 20100906
- international:
G01N33/68
- cooperative:
G01N33/57419; G01N2333/515; G01N2800/52; G01N2800/56
Patent application
2262
德國
